D2 and 5HT2 receptors: Relevance to antipsychotic drugs

Indian Journal of Pharmacology

Volumn 32, Issue 3, 2000, Pages 187-191

  Karan, R S ^a   Pandhi, P ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

5 HT2 receptors; Atypical antipsychotics; D2

Indexed keywords

CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SERTINDOLE;

DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NIGRONEOSTRIATAL SYSTEM; RECEPTOR DOWN REGULATION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA;

EID: 0033917341     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Snyder SH. The dopamine hypothesis of schizophrenia: Focus on dopamine receptor. Am J Psych 1976;133:197-202.
2. Meltzer HY, Stahi SM. The dopamine hypothesis of schizophrenia : A review. Schizophr Bull 1976;2:19-76.
3. 2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psych 1999;156:286-93.
4. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995;14:187-202.
5. Iqbal N, Van Praag HM. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995;5:11-23.
6. 18F] setoperone in neuroleptic-naïve patients and normal subjects. Am J Psych 1999;156:72-8.
7. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 976;261:717-9.
8. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psych 1996; 153:466-76.
9. Ohuoha DC, Hyde TM, Kleinman JE. The role of serotonin in schizophrenia : an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacol 1993;112:S5-S15.
10. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995;15:2S-3S.
11. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine:relation to extrapyramidal side effects. Arch Gen Psych 1992;49: 538-44.
12. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psych 1984;151:825-35.
13. Tollefson GD, Beasky CM, Tran PV, Street JS, Krueger JA, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psych 1997;154:457-65.
14. 2-dopamine receptor occupancy in relation to antipsychotic drug effects-a double-blind PET study of schizophrenic patients. Biol Psych 1993;33:227-35.
15. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacol 1989;99:463-72.
16. 2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacol 1996;124:285-7.
17. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psych 1989;146:905-8.
18. Kane JM, Freeman HL. Towards more effective antipsychotic treatment. Br J Psych 1994;165:22-31.
19. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, et al. Sertindole study group: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psych 1997;154:782-91.
20. 2 receptor occupancy in relation to clozapine serum concentration : a PET study of schizophrenic patients. Am J Psych 1995;152:1444-9.
21. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15:19-23.
22. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacol 1997;1:1-7.
23. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psych 1996;153:948-50.
24. 2 dopamine receptor mRNAs in the primate cerebral cortex vs neostriatum: Effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997;283:939-46.
25. 2 dopamine receptors in the primate cerebral cortex. Proc Natl Acad Sci 1994;91:4353-6.
26. Eggers C, Rothenberger A, Berghans U. Clinical and neurobiological findings in children suffering from disease following treatment with tiapride. Eur Arch Psychiar Neurol Sci 1988;237:223-9.
27. Deutch AY, Maghaddam B, Innis RB, Krystal JH, Aghajanian GK, et al. Mechanism of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-56.
28. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacol 1995;13:177-213.
29. 4. Neuropsychopharmacol 1992;7:261-84.
30. 4 receptors in rat frontal cortex. J Neurol Transm 1995;101:231-5.
31. 4 receptors elevated in schizophrenia. Nature 1993a;365:441-5.
32. 4 receptor gene: Frequent occurrence of a null allele and observations of the homozygosity. Human Mol Genetics 1994;3:2207-12.
33. 4 glicine 194 in Africans, but not in Caucasians: No association with schizophrenia. Am J Med Genet 1994;54:384-90,
34. 1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-5.
35. Meltzer HY, Masubara S, Lee JC. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25:390-2.
36. 2 and serotonin-2 pK1 values. J Pharmacol Exp Ther 1989;251:238-46.
37. Kapur S. A new frame work for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998;3:135-40.
38. Schotte A, Janssen PEM, Gommeren W, Luyten WHML, VanGompel P, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol 1996;124:57-73.
39. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine-a I-123 IBZM single photon emission tomography (SPET) study. Psychopharmacol 1996;124:148-53.
40. VanderZwaag C, McGee M, McEvoy JR Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psych 1996;153:1579-84.
41. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psych 1998;155:505-8.
42. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psych 1998; 155:921-8.
43. 2A antagonist Fananserin in the treatment of schizophrenia. Am J Psych 1999;156:419-25.
44. 2A receptor occupancy in schizophrenic patients. Am J Psych 1999;156:869-75.